These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 14870993)

  • 1. Use of IGIV in the treatment of immune-mediated dermatologic disorders.
    Gelfand EW
    J Investig Dermatol Symp Proc; 2004 Jan; 9(1):92-6. PubMed ID: 14870993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous immunoglobulin in autoimmune disorders: an insight into the immunoregulatory mechanisms.
    Bayry J; Dasgupta S; Misra N; Ephrem A; Duong Van Huyen JP; Delignat S; Hassan G; Caligiuri G; Nicoletti A; Lacroix-Desmazes S; Kazatchkine MD; Kaveri S
    Int Immunopharmacol; 2006 Apr; 6(4):528-34. PubMed ID: 16504915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Regulation of autoreactivity by the idiotypic network and therapeutic modulation of autoimmunity by polyvalent intravenous immunoglobulins (IgIV)].
    Lacroix-Desmazes S; Kaveri S; Kazatchkine MD
    Rev Neurol (Paris); 1996 May; 152(5):349-54. PubMed ID: 8881428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of intravenous immunoglobulin therapy in autoimmune blistering diseases.
    Ahmed AR
    Int Immunopharmacol; 2006 Apr; 6(4):557-78. PubMed ID: 16504919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of cost of immune globulin intravenous therapy to conventional immunosuppressive therapy in treating patients with autoimmune mucocutaneous blistering diseases.
    Daoud YJ; Amin KG
    Int Immunopharmacol; 2006 Apr; 6(4):600-6. PubMed ID: 16504922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Intravenous immunoglobulins (IgIV) in the treatment of autoimmune diseases and systemic inflammatory diseases].
    Kazatchkine M
    Nouv Rev Fr Hematol (1978); 1993 Jun; 35(3):209-10. PubMed ID: 8337128
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical and investigational considerations for the use of IGIV therapy.
    Ballow M
    Am J Health Syst Pharm; 2005 Aug; 62(16 Suppl 3):S12-8; quiz S19-21. PubMed ID: 16100383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective.
    Sibéril S; Elluru S; Graff-Dubois S; Negi VS; Delignat S; Mouthon L; Lacroix-Desmazes S; Kazatchkine MD; Bayry J; Kaveri SV
    Ann N Y Acad Sci; 2007 Sep; 1110():497-506. PubMed ID: 17911465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous immunoglobulin and autoimmune disease.
    El-Shanawany T; Jolles S
    Ann N Y Acad Sci; 2007 Sep; 1110():507-15. PubMed ID: 17911466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous immune globulins. A review of their uses in selected immunodeficiency and autoimmune diseases.
    Pirofsky B; Kinzey DM
    Drugs; 1992 Jan; 43(1):6-14. PubMed ID: 1372861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The patient: Emerging clinical applications of intravenous immunoglobulin.
    Harvey RD
    Pharmacotherapy; 2005 Nov; 25(11 Pt 2):85S-93S. PubMed ID: 16229679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous immunoglobulin: an emerging treatment for immune-mediated skin diseases.
    Rütter A; Luger TA
    Curr Opin Investig Drugs; 2002 May; 3(5):713-9. PubMed ID: 12090544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunomodulation with intravenous immunoglobulin.
    Hall PD
    Pharmacotherapy; 1993; 13(6):564-73. PubMed ID: 8302679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Intravenous immunoglobulins in hematologic therapy].
    Giovanelli E
    Clin Ter; 1992 Sep; 141(9 Pt 2):69-73. PubMed ID: 1468201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology.
    Orange JS; Hossny EM; Weiler CR; Ballow M; Berger M; Bonilla FA; Buckley R; Chinen J; El-Gamal Y; Mazer BD; Nelson RP; Patel DD; Secord E; Sorensen RU; Wasserman RL; Cunningham-Rundles C;
    J Allergy Clin Immunol; 2006 Apr; 117(4 Suppl):S525-53. PubMed ID: 16580469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma exchange and intravenous immunoglobulins: mechanism of action in immune-mediated neuropathies.
    Lehmann HC; Hartung HP
    J Neuroimmunol; 2011 Feb; 231(1-2):61-9. PubMed ID: 21056913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose intravenous immunoglobulins: an approach to treat severe immune-mediated and autoimmune diseases of the skin.
    Rütter A; Luger TA
    J Am Acad Dermatol; 2001 Jun; 44(6):1010-24. PubMed ID: 11369915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Practical considerations for the use of IGIV therapy: introduction.
    Shah S
    Am J Health Syst Pharm; 2005 Aug; 62(16 Suppl 3):S3-4. PubMed ID: 16100385
    [No Abstract]   [Full Text] [Related]  

  • 19. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases.
    Yu Z; Lennon VA
    N Engl J Med; 1999 Jan; 340(3):227-8. PubMed ID: 9895405
    [No Abstract]   [Full Text] [Related]  

  • 20. [Use of intravenous polyclonal immunoglobulins in autoimmune and inflammatory disorders].
    Graff-Dubois S; Sibéril S; Elluru S; Negi VS; Delignat S; Mouthon L; Lacroix-Desmazes S; Kazatchkine MD; Bayary J; Kaveri SV
    Transfus Clin Biol; 2007 May; 14(1):63-8. PubMed ID: 17498995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.